Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — FY2024 Earnings Presentation
16 slides from Tarsus Pharmaceuticals's earnings presentation, Feb 25, 2025
Slide 1: Fourth Quarter and Full-Year 2024 Financial Results Conference Call
Fourth Quarter and Full-Year 2024 Financial Results Conference Call February 25, 2025 Matt, an XDEMVY® Patient
Slide 2: Today’s Speakers
Today’s Speakers Bobby Azamian, MD, PhD Jeff Farrow Aziz Mottiwala Sesha Neervannan, PhD CEO & Chairman Chief Financial & Strategy Officer Chief Commercial Officer Chief Operating Officer 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements include statements regarding the potential commercial success and growth of XDEMVY in Demodex blepharitis, including market size, acceptance, demand, and adoption r
Slide 4: Tarsus: A Leader in Eye Care
Tarsus A Leader in Eye Care Proven Blueprint XDEMVY® Ocular Rosacea For Creating Accelerating Toward A New Potentially New Categories Potential Blockbuster Status Transformational Opportunity • Expert leadership team with an • The first and only FDA-approved • Another impactful eye disease expansive
Slide 5: XDEMVY: Driving One of the Fastest Growing Categories in Eye Care
XDEMVY Driving One of the Fastest Growing Categories in Eye Care1 >$180M Net product sales >163K Bottles delivered to patients >15K Prescribing ECPs2 >90% Commercial, Medicare & Medicaid Lives Covered3 In Just One Year, XDEMVY has Become One of the Best Launches in Eye Care Abby, an XDEMVY patient.
Slide 6: The Next Impactful Area of Unmet Need
The Next Impactful Area of Unmet Need Ocular Rosacea Demodex Blepharitis (DB) Ocular Rosacea (OR) • Caused by Demodex mites • Caused by Demodex mites • Eyelid inflammation, redness, irritation, • Eye and eyelid inflammation and redness, collarettes prominent and visible blood vessels • Quick and sim
Slide 7: Setting a New Standard in Product Launches
Setting a New Standard in Product Launches Changing ECP practice patterns and increasing utilization across >15,000 ECPs1 Strong commercial, Medicare and Medicaid coverage now extends to >90% of covered lives2 Expanded sales force starting to deliver a meaningful increase in prescriptions The first
Slide 8: XDEMVY: First Pharmacologic Treatment to Demonstrate Groundbreaking Improvements in MGD
XDEMVY: First Pharmacologic Treatment To Demonstrate Groundbreaking Improvements in MGD and Patient Symptoms in DB Patients Combined data1 in patients with DB and MGD Improvement in Objective Improvements in demonstrated statistically significant and Measures of Meibomian Patient Symptoms – clinical
Slide 9: Making XDEMVY a Household Name
Making XDEMVY a Household Name Direct-To-Consumer Campaign Driving Patients to ECPs The GRAMMY Awards 9 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 10: Upcoming Potential Value Driving Catalysts
Upcoming Potential Value Driving Catalysts Greater U.S. Europe Japan China* TP-04 for Ocular Rosacea: XDEMVY for DB: TP-03 for DB: TP-03 for DB: Plans to initiate Ph 2 trial in 2H 2025 On-track for potential regulatory Initial results from a prevalence New Drug Application accepted TP-05 for Lyme ap
Slide 11: The Next Impactful Area of Unmet Need
The Next Impactful Area of Unmet Need Ocular Rosacea Demodex Blepharitis (DB) Ocular Rosacea (OR) • Caused by Demodex mites • Caused by Demodex mites • Eyelid inflammation, redness, irritation, • Eye and eyelid inflammation and redness, collarettes prominent and visible blood vessels • Quick and sim
Slide 12: TP-04: Potential to Pioneer the Standard of Care for Ocular Rosacea
TP-04 Potential to Pioneer the Standard of Care for Ocular Rosacea Targets Root Cause of Disease Demodex mites Uniquely Tailored Sterile Ophthalmic Gel Specifically designed to be applied to the eyelid and surrounding tissue Potential Best-in-Class Molecule Lotilaner - poised to deliver another pote
Slide 13: TP-05: Potential to Be the First and Only Durable, On-Demand Oral Prophylaxis for Lyme Disease
TP-05: Potential to Be the First and Only Durable, On-Demand Oral Prophylaxis for Lyme Disease TP-05 A D VA N C I N G Phase 2 Trial To inform: Safety • Dosage • Lyme prevention Prevention is Key: Patient Impact: TP-05: Strong physician/patient interest in a Difficult to manage; long-term Fast- and l
Slide 14: Financial Results
Financial Results XDEMVY: On-track to potentially be one of the best launches in eye care XDEMVY Net Sales XDEMVY Bottles ($ in millions) Delivered to Patients $66.4 (in thousands) $48.1 58.5 $40.8 37.0 41.4 $24.7 26.0 $13.1 15.0 $1.7 1.7 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q3 2023 Q4 20
Slide 15: Tarsus: A Leader in Eye Care
Tarsus A Leader in Eye Care Proven Blueprint XDEMVY® Ocular Rosacea For Creating Accelerating Toward A New Potentially New Categories Potential Blockbuster Status Transformational Opportunity • Expert leadership team with an • The first and only FDA-approved • Another impactful eye disease expansive
Slide 16: Q&A
Q&A Bobby Azamian, MD, PhD Jeff Farrow Aziz Mottiwala Sesha Neervannan, PhD CEO & Chairman Chief Financial & Strategy Officer Chief Commercial Officer Chief Operating Officer 16 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Tarsus Pharmaceuticals — FY2024 Earnings Presentation on 6ix